Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 79 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]
2. Cita con resumen
Tsai W-C, Wu H-Y, Peng Y-S, Yang J-Y, Chen HY, Chiu Y-L, Hsu S-P, Ko M-J, Pai M-F, Tu Y-K, Hung K-Y, Chien K-L. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017;177:792-9. [Ref.ID 101619]
3. Cita con resumen
Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, for the VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016;316:509-18. [Ref.ID 100687]
4. Cita con resumen
van Dalem J, Brouwers MCGJ, Stehouwer CDA, Krings A, Leufkens HGM, Driessen JHM, de Vries F, Burden AM. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ 2016;354:i3625. [Ref.ID 100570]
5. Cita con resumen
Anónimo. Thalidomide: reduced starting dose in patients older than age 75 years. Drug Safety Update 2015;9:2. [Ref.ID 99746]
6. Cita con resumen
Sennesael AL, Dogné J-M, Spinewine A. Optimizing the safe use of direct oral anticoagulants in older patients. A teachable moment. JAMA Intern Med 2015;175:1608-9. [Ref.ID 99648]
7.Enlace a cita original Cita con resumen
Caldeira D, Gonçalves N, Pinto FJ, Costa J, Ferreira J. Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2015;24:757-64. [Ref.ID 99318]
8. Cita con resumen
Perry TL. Scant evidence on the effectiveness of metformin in type 2 diabetes. BMJ 2015;350:h2650. [Ref.ID 99116]
9. Cita con resumen
Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis 2015;65:701-9. [Ref.ID 99105]
10. Cita con resumen
Roberts E, Nunes VD, Buckner S, Latchem S, Constanti M, Miller P, Doherty M, Zhang W, Birrell F, Porcheret M, Dziedzic K, Bernstein I, Wise E, Conaghan PG. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2015:4 de marzo. [Ref.ID 98867]
11. Cita con resumen
Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY-J, Jorgensen M, Dua A, Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014;383:1814-23. [Ref.ID 97631]
12.Tiene citas relacionadas
Shlipak MG, Coresh J, Gansevoort RT. Cystatin C versus creatinine for kidney function-based risk. The authors reply. N Engl J Med 2013;369:2459. [Ref.ID 96682]
13.Tiene citas relacionadas
Vandecasteele SJ, De Vriese AS. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458-9. [Ref.ID 96681]
14.Tiene citas relacionadas Cita con resumen
Cherney D, Maahs DM. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458. [Ref.ID 96680]
15.Tiene citas relacionadas Cita con resumen
Tavares Jr AR. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2457-8. [Ref.ID 96679]
16.Tiene citas relacionadas Cita con resumen
Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. The authors reply. N Engl J Med 2013;369:1379-80. [Ref.ID 96341]
17.Tiene citas relacionadas Cita con resumen
Tanimoto T, Oshima Y, Kami M. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1378-9. [Ref.ID 96340]
18.Tiene citas relacionadas Cita con resumen
Kistler AD. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1378. [Ref.ID 96339]
19.Tiene citas relacionadas Cita con resumen
Amadio A, Tejani AM. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1378. [Ref.ID 96338]
20.Tiene citas relacionadas Cita con resumen
Ring T. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1377-8. [Ref.ID 96337]
Seleccionar todas
 
 1 a 20 de 79 siguiente >>